Tuesday, May 1, 2018

Attenua Picks Up $35M to Treat Chronic Cough

Mountain View-based biopharmaceuticals startup Attenua, which is developing medicines to treat chronic cough, has raised $35M in a Series A funding. The funding was led by Omega Funds, and also included Abingworth, OrbiMed and Redmile Group. Attenua said that, as part of the funding, Michael Kitt, M.D., the former Chief Medical Officer at Afferent Pharmaceuticals, has been named CEO of the company.